State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University , Guangzhou, China .
J Ocul Pharmacol Ther. 2017 Mar;33(2):103-110. doi: 10.1089/jop.2016.0163. Epub 2017 Jan 20.
To design an MG132-sustained drug delivery capsular ring (SDDCR) and investigate its effect on the inhibition of posterior capsule opacification (PCO) in a rabbit model.
The SDDCRs were prepared by forming a slice of film made by the mixture of poly lactic-co-glycolic acid (PLGA) and MG132 on the surface of capsular tension rings (CTRs). The drug-loading capacity, entrapment efficiency, and in vitro release of the drug-containing film were detected. Eighteen New Zealand white rabbits were operated with phacoemulsification and MG132-SDDCRs/PLGA-CTRs/CTRs implantation in the single eye. The images of the anterior segments were acquired at certain days, and the epithelial-mesenchymal transition (EMT) markers were detected by western blot and immunofluorescence.
The drug-loading capacity and entrapment efficiency of MG132-SDDCRs were 1.15% ± 0.04% and 66.16% ± 0.027%, respectively, and the drug released well within a month. The PCO degree of the MG132-SDDCR group was significantly lower than the other groups. The expression of alpha-smooth muscle actin, fibronectin, vimentin, and collagen-I was lower, and the expression of E-cadherin (E-cad) was higher in the MG132-SDDCR group than the other groups.
MG132-SDDCRs could be established successfully. The PCO process was prevented, and the expression of EMT markers was inhibited by the implantation of MG132-SDDCRs, indicating that this could be a potential treatment against PCO.
设计一种含 MG132 的药物维持性巩膜扣带环（SDDCR），并在兔模型中观察其对后发性白内障（PCO）抑制的作用。
在巩膜扣带环（CTR）表面形成聚乳酸-共-羟基乙酸（PLGA）和 MG132 混合物制成的膜片，制备 SDDCR。检测载药膜的载药量、包封率和体外释放。将 18 只新西兰白兔行超声乳化白内障吸除术，单眼植入 MG132-SDDCR/PLGA-CTR/CTR。在特定天数获取眼前节图像，通过 Western blot 和免疫荧光检测上皮-间充质转化（EMT）标志物。
MG132-SDDCR 的载药量和包封率分别为 1.15%±0.04%和 66.16%±0.027%，并且在一个月内药物释放良好。MG132-SDDCR 组的 PCO 程度明显低于其他组。MG132-SDDCR 组的α-平滑肌肌动蛋白、纤维连接蛋白、波形蛋白和胶原-I 的表达较低，E-钙黏蛋白（E-cad）的表达较高。
MG132-SDDCR 可成功构建。植入 MG132-SDDCR 可防止 PCO 过程，并抑制 EMT 标志物的表达，表明这可能是一种治疗 PCO 的潜在方法。
